Ivanna Subtelna

@new.meduniv.lviv.ua

department of pharmaceutical, organic and bioorganic chemistry
Danylo Halutsky Lviv National Medical University

Ivanna Subtelna


                  Download Compact PDF  
https://researchid.co/subtelna_i

RESEARCH, TEACHING, or OTHER INTERESTS

Organic Chemistry, Pharmaceutical Science, Drug Discovery
11

Scopus Publications

440

Scholar Citations

9

Scholar h-index

9

Scholar i10-index

Scopus Publications

  • Anticancer 5-arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones as tubulin inhibitors
    Jiri Rehulka, Ivanna Subtelna, Anna Kryshchyshyn‐Dylevych, Alina Cherniienko, Aleksandra Ivanova, et al.
    Archiv Der Pharmazie, 2022
    Studying the anticancer activity of 5‐arylidene‐2‐(4‐hydroxyphenyl)aminothiazol‐4(5H)‐ones towards cell lines of different cancer types allowed the identification of hit‐compounds inhibiting the growth of daunorubicin‐ (CEM‐DNR, IC50 = 0.32–1.28 µM) and paclitaxel‐resistant (K562‐TAX, IC50 = 0.21–1.23 µM) cell lines, with favorable therapeutic indexes. The studied compounds induced apoptosis and cellular proliferation in treated CCRF‐CEM cells. The hit compounds were shown to induce mitotic arrest by interacting with tubulin, inhibiting its polymerization by binding to the colchicine binding site.
  • Anticancer cytotoxicity of indole-thiazolidinone hybrids, in silico study of mechanisms of their action
    A. P. Kryshchyshyn-Dylevych, I. Y. Subtelna, N. S. Finiuk, L. Radko, A. Pawełczyk, et al.
    Biopolymers and Cell, 2022
  • 5-Arylidene-2-(4-hydroxyphenyl)aminothiazol-4(5H)-ones with selective inhibitory activity against some leukemia cell lines
    Ivanna Subtelna, Anna Kryshchyshyn‐Dylevych, Ruochen Jia, Maryan Lelyukh, Anna Ringler, et al.
    Archiv Der Pharmazie, 2021
    The data on the pharmacology of 4‐thiazolidinones showed that 5‐ene‐2‐(imino)amino‐4‐thiazolidinones are likely to comprise one of the most promising groups of compounds possessing anticancer properties. A series of 5‐arylidene‐2‐(4‐hydroxyphenyl)aminothiazol‐4(5H)‐ones was designed, synthesized, and studied against 10 leukemia cell lines, including the HL‐60, Jurkat, K‐562, Dami, KBM‐7, and some Ba/F3 cell lines. The structure–activity relationship analysis shows that almost all tested 5‐arylidene‐2‐(4‐hydroxyphenyl)aminothiazol‐4(5H)‐ones were characterized by ІС50 values lower or comparable to that of the control drug chlorambucil. Among the tested compounds, (5Z)‐5‐(2‐methoxybenzylidene)‐ (12), (5Z)‐(2‐ethoxybenzylidene)‐ (21), (5Z)‐5‐(2‐benzyloxybenzylidene)‐ (25), and (5Z)‐5‐(2‐allyloxybenzylidene)‐2‐(4‐hydroxyphenylamino)thiazol‐4(5H)‐ones (28) possessed the highest antileukemic activity at submicromolar concentrations (ІС50 = 0.10–0.95 µM).
  • In silico identification and biochemical validation of plausible molecular targets of 4-thiazolidinone derivative les-3833 as a potential anticancer agent
    L. Kоbylinska, D. Khylyuk, I. Subtelna, M. Kitsera, R. Lesyk, et al.
    Ukrainian Biochemical Journal, 2021
    Synthetic 4-thiazolidinone derivatives have a broad range of pharmacologic activities. Thus, 4-thia-zolidinones are being investigated to create new molecules and develop active pharmaceutical substances for anticancer treatment. In our previous study, we investigated the pyrazoline-thiazolidinone-isatin conjugates, and determined that Les-3833 was the most active compound and might act through inhibition of ParP-, MaPK-, JnK-, bcl-2-, CDK1/cyclin b, and/or the caspase family. the aim of this research was to perform molecular docking studies to enable the construction of a pharmacophore model for the Les-3833 compound and investigate probable biological targets. Pharmacophore modeling software packages performed molecular docking studies of probable biological targets and enabled the construction of a pharmacophore model. Docking models of Les-3833 with 11 enzymes involved in apoptotic mechanisms were studied. Based on the pharmacophore modeling results for all 11 enzymes, Les-3833 is predicted to be most active in Chk-1, caspase-6, and caspase-8. Immunoblot analysis proved that the application of Les-3833 led to inhibition of ser345 phosphorylation, which is induced by etoposide, the most important modification responsible for Chk-1 activity. Taken together with the results of the docking studies, several mechanisms for the expression of antitumor activity by 4-thiazolidinones are suggested, and such multi-affinity is a characteristic feature of all these derivatives. the docking analysis confirmed the affinity of test compound Les-3833 for a topoisomerase II inhibitor and a high possibility of inhibitory interaction with Chk-1, caspase-6, and caspase-8.
  • One-Pot Synthesis of 5-Ene-4-aminothiazol-2(5H)-ones and Chromeno[2,3-d]thiazol-2-ones
    Roman Lesyk, Danylo Kaminskyy, Ivanna Subtel’na, Andriy Pyrih, Danylo Shtoyko, et al.
    Synlett, 2017
    Herein, we describe a one-pot, three-component method for the synthesis of 5-arylidene-4-aminothiazol-2(5H)-ones based on the reaction of isorhodanine, aromatic aldehydes, and ethanolamine. The one-pot procedure for chromeno[2,3-d]thiazol-2-one synthesis starting from 4-aminothiazol-2(5H)-one was proposed following the study of 5-(2-hydroxybenzylidene)-thiazolidinones. Structural features of the starting 4-thioxo-2-thiazolidinone, 4-aminothiazol-2(5H)-one, and target compounds are discussed.
  • Synthesis and evaluation of anticancer activity of 5-ylidene-4-aminothiazol-2(5H)-one derivatives
    Danylo Kaminskyy, Ivanna Subtel’na, Borys Zimenkovsky, Olexandr Karpenko, Andrzej Gzella, et al.
    Medicinal Chemistry, 2015
    The synthesis and antitumor activity screening of 4-aminothiazol-2(5H)-one derivatives were performed. The absence of possible 4-amino-imino tautomerism of thiazolidinones-2 has been confirmed based on the study of the molecule structures. The existence of the alone amino-form was confirmed. An anticancer activity screening was performed within the Developmental Therapeutics Program (National Cancer Institute/NIH, USA). Tested compounds possess low to moderate anticancer activity (average values - 60 cancer cell lines assay) with significant selective action on certain cancer cell lines (CCRF-CEM and RPMI-8226/leukemia, U251/CNS cancer, RFX 393/renal cancer, OVCAR/ovarian cancer etc.). The advantage of 5-ylidene-4-R-amino derivatives in comparison with compounds with free amino group was shown. Some structure-activity findings, the comparison of target compounds with isomeric 5-ylidene-2-imino(amino)thiazol-4(5H)-ones, as well as COMPARE analysis were described. Among the tested compounds (Z)-5-(furan-2-ylmethylidene)-4-(4-chlorophenylamino)thiazol-2(5H)-one (IIIk) and (Z)-5-(4-diethylaminophenylmethylidene)-4-(4-hydroxy-5-isopropyl-2-methylphenylamino)thiazol-2(5H)-one (IIIp) possessed the highest levels of activity.
  • Thiazolidinone motif in anticancer drug discovery. Experience of DH LNMU medicinal chemistry scientific group
    R. B. Lesyk, B. S. Zimenkovsky, D. V. Kaminskyy, A. P. Kryshchyshyn, D. Ya. Havryluk, et al.
    Biopolymers and Cell, 2011
    The aim was analysis of 4-thiazolidinones and related heterocyclic systems anticancer activity data and formation of some rational design directions of potential anticancer agents. Synthetic research carried out in Danylo Halytsky Lviv National Medical University (DH LNMU) allowed us to propose a whole number of new molecular design directions of biological active 4-thiazolidinones and related heterocyclic systems, as well as obtain directed library that numbers over 5000 of novel compounds. At the present time in vitro anticancer activity screening was carried out for more than 1000 compounds (US NCI protocol (Developmental Therapeutic Program), among them 167 compounds showed high antitumor activity level. For the purpose of optimization and rational design of highly active molecules with optimal «drug-like» characteristics and discovering of possible mechanism of action SAR, QSAR analysis and molecular docking were carried out. The ultimate aim of the project is creating of innovative synthetic drug with special mechanism of action and sufficient pharmacological and toxicological features. Some aspects of structure–act ivity relationships were determined and structure design directions were proposed. The series of active compounds with high anticancer activity and/or selectivity levels were selected.
  • Synthesis and antitumor activity evaluation of new 2-(4-alkoxyphenylamino) thiazol-4(5H)-onesderivatives
    Annales Universitatis Mariae Curie Sklodowska Sectio Ddd Pharmacia, 2010
  • Synthesis of 5-arylidene-2-amino-4-azolones and evaluation of their anticancer activity
    Ivanna Subtel’na, Dmytro Atamanyuk, Ewa Szymańska, Katarzyna Kieć-Kononowicz, Borys Zimenkovsky, et al.
    Bioorganic and Medicinal Chemistry, 2010
  • Synthesis and antiinflammatory activity of some 2-arylamino-2-thiazoline-4-ones
    Acta Poloniae Pharmaceutica Drug Research, 2003
  • The structure - anti-inflammatory activity relationship among thiazolidones: Conclusion from scientific programme
    Journal of Pharmacy and Pharmacology, 1999

RECENT SCHOLAR PUBLICATIONS

  • Anticancer 5‐arylidene‐2‐(4‐hydroxyphenyl)aminothiazol‐4(5 H )‐ones as tubulin inhibitors
    J Rehulka, I Subtelna, A Kryshchyshyn‐Dylevych, A Cherniienko, ...
    Archiv der Pharmazie 355 (12), 2200419 , 2022
    2022
    Citations: 16
  • Протипухлинна цитотоксичність індол-тіазолідинонових гібридів та in silico дослідження механізму їхньої дії
    АП Крищишин-Дилевич, ІЮ Субтельна, НС Фінюк, Л Радко, ...
    Biopolymers and Cell 38 (4), 257-277 , 2022
    2022
  • Anticancer cytotoxicity of indole-thiazolidinone hybrids, in silico study of mechanisms of their action
    AP Kryshchyshyn-Dylevych, IY Subtelna, NS Finiuk, L Radko, ...
    Biopolymers and Cell 38 (4), 257-277 , 2022
    2022
    Citations: 2
  • 5‐Arylidene‐2‐(4‐hydroxyphenyl)aminothiazol‐4(5 H )‐ones with selective inhibitory activity against some leukemia cell lines
    I Subtelna, A Kryshchyshyn‐Dylevych, R Jia, M Lelyukh, A Ringler, ...
    Archiv der Pharmazie 354 (4), 2000342 , 2021
    2021
    Citations: 11
  • In sIlIco identification and biochemical validation of plausible molecular targets of 4-thiazolidinone derivative les-3833 as a potential anticancer agent
    RL L. KоbylinsKa, D. Khylyuk, I. Subtelna, M. Kitsera
    Ukrainian Biochemical Journal 93 (2), 7-22 , 2021
    2021
    Citations: 1
  • One-Pot Synthesis of 5-Ene-4-aminothiazol-2 (5H)-ones and Chromeno [2, 3-d] thiazol-2-ones
    D Kaminskyy, I Subtel’na, A Pyrih, D Shtoyko, A Susel, A Gzella, R Lesyk
    Synlett 28 (07), 811-814 , 2017
    2017
    Citations: 12
  • Synthesis and evaluation of anticancer activity of 5-ylidene-4-aminothiazol-2 (5H)-one derivatives
    D Kaminskyy, I Subtel’na, B Zimenkovsky, O Karpenko, A Gzella, R Lesyk
    Medicinal Chemistry 11 (6), 517-530 , 2015
    2015
    Citations: 34
  • Синтез, превращения и биологическая активность функциональнозамещенных 2-амино-2-тиазолин-4-онов и 2(4)-имино-4(2)-тиазолидинонов
    Д.Я. Гаврилюк, И.Ю. Субтельная, Б.С. Зименковский
    “Химия и биологическая активность азолов” (Избранные обзоры) под редакцией В … , 2014
    2014
  • Rational design of potential anticancer" drug-like" molecules based on 4-azoldinone scaffold
    R Lesyk, B Zimenkovsky, D Kaminskyy, D Havryluk, D Atamanyuk, ...
    EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS 40, 109-109 , 2011
    2011
  • RECOOP Biopolymers and Cell
    SG Vari
    Biopolymers & Cell 27 (2) , 2011
    2011
  • Thiazolidinone motif in anticancer drug discovery. Experience of DH LNMU medicinal chemistry scientific group
    RB Lesyk, BS Zimenkovsky, DV Kaminskyy, AP Kryshchyshyn, ...
    Biopolymers and Cell 27 (2), 107-117 , 2011
    2011
    Citations: 141
  • Тіазолідинони як лейтмотив у створенні протиракових лікарських засобів. Досвід наукової групи з медичної хімії ЛНМУ імені Данила Галицького
    РБ Лесик, БС Зіменковський, ДВ Камінський, АП Крищишин, ...
    Biopolymers and Cell 27 (2), 107-117 , 2011
    2011
  • Synthesis and antitumor activity evaluation of new 2-(4-alkоxyphenylamino) thiazol-4 (5H)-оnes derivatives
    I Subtel’na, B Zimenkovsky, R Lesyk
    Current Issues in Pharmacy and Medical Sciences 23 (3), 231-235 , 2010
    2010
    Citations: 1
  • Synthesis of 5-arylidene-2-amino-4-azolones and evaluation of their anticancer activity
    I Subtel’na, D Atamanyuk, E Szymańska, K Kieć-Kononowicz, ...
    Bioorganic & medicinal chemistry 18 (14), 5090-5102 , 2010
    2010
    Citations: 126
  • SzymaÅ „ska E, Kieć-Kononowicz K, Zimenkovsky, B, Vasylenko O, Gzella A, Lesyk R. Synthesis of 5-arylidene-2-amino-4-azolones and evaluation of their anticancer activity
    I Subtel’na, D Atamanyuk
    Bioorg Med Chem 18, 5090-102 , 2010
    2010
    Citations: 4
  • СИНТЕЗ И ИЗУЧЕНИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТИ ПРОИЗВОДНЫХ 2-(4-АЛКОКСИ-ФЕНИЛАМИНО) ТИАЗОЛ-4 (5Н)-ОНОВ
    ІЮ Субтельна, БС Зіменковський, РБ Лесик
    Журнал органічної та фармацевтичної хімії 8 (3), 58-64 , 2010
    2010
  • СИНТЕЗ 5-АРИЛІДЕНПОХІДНИХ (2-МЕТИЛ-4-ОКСИ-5-ІЗОПРОПІЛФЕНІЛАМІНО) ТІАЗОЛОНІВ ТА ВИВЧЕННЯ ЇХ ПРОТИПУХЛИННОЇ АКТИВНОСТІ
    ІЮ Субтельна, БС Зіменковський, А Гзелля, ГМ Семенців, ...
    Клінічна фармація, фармакотерапія та медична стандартизація, 93 , 2010
    2010
  • Синтез та вивчення протипухлинної активності похідних 2-(4-алкоксифеніламіно) тіазол-4 (5Н)-онів
    ІЮ Субтельна, БС Зіменковський, РБ Лесик
    Інститут органічної хімії НАН України , 2010
    2010
  • Anticancer potential of 4-azolidones and related heterocycles
    R Lesyk, B Zimenkovsky, D Kaminskyy, S Holota, D Atamanyuk, ...
    Ann. Univ. Mariae Curie-Sklodowska. Med 19 (1), 107-110 , 2006
    2006
    Citations: 19
  • Effective approach to obtaining combinatorial library of heterocycles with thioisocoumarine template (in Ukrainian)
    R.B. Lesyk, B.S. Zimenkovsky, I.Yu. Subtel`na, I.I. Soronovych, G.M ...
    Фармацевтичний журнал / Farmacevtychnyj Zhurnal 2003 (03), 56-60 , 2003
    2003

MOST CITED SCHOLAR PUBLICATIONS

  • Thiazolidinone motif in anticancer drug discovery. Experience of DH LNMU medicinal chemistry scientific group
    RB Lesyk, BS Zimenkovsky, DV Kaminskyy, AP Kryshchyshyn, ...
    Biopolymers and Cell 27 (2), 107-117 , 2011
    2011
    Citations: 141
  • Synthesis of 5-arylidene-2-amino-4-azolones and evaluation of their anticancer activity
    I Subtel’na, D Atamanyuk, E Szymańska, K Kieć-Kononowicz, ...
    Bioorganic & medicinal chemistry 18 (14), 5090-5102 , 2010
    2010
    Citations: 126
  • Synthesis and antiinflammatory activity of some 2-arylamino-2-thiazoline-4-ones
    Roman Lesyk, Boris Zimenkovsky, Ivanna Subtelna, Igor Nektegayev, Gennadij ...
    Acta poloniae pharmaceutica 60 (6), 457-466 , 2003
    2003
    Citations: 46
  • Synthesis and evaluation of anticancer activity of 5-ylidene-4-aminothiazol-2 (5H)-one derivatives
    D Kaminskyy, I Subtel’na, B Zimenkovsky, O Karpenko, A Gzella, R Lesyk
    Medicinal Chemistry 11 (6), 517-530 , 2015
    2015
    Citations: 34
  • The structure – anti-inflammatory activity relationship among thiazolidones: conclusion from scientific programme
    IC B. Zimenkovsky, O.Vladzimirska, R.Lesyk, I. Nektegayev, S. Golota
    Journal of Pharmacy and Pharmacology 51 (3), 264 , 1999
    1999
    Citations: 22
  • Anticancer potential of 4-azolidones and related heterocycles
    R Lesyk, B Zimenkovsky, D Kaminskyy, S Holota, D Atamanyuk, ...
    Ann. Univ. Mariae Curie-Sklodowska. Med 19 (1), 107-110 , 2006
    2006
    Citations: 19
  • Anticancer 5‐arylidene‐2‐(4‐hydroxyphenyl)aminothiazol‐4(5 H )‐ones as tubulin inhibitors
    J Rehulka, I Subtelna, A Kryshchyshyn‐Dylevych, A Cherniienko, ...
    Archiv der Pharmazie 355 (12), 2200419 , 2022
    2022
    Citations: 16
  • One-Pot Synthesis of 5-Ene-4-aminothiazol-2 (5H)-ones and Chromeno [2, 3-d] thiazol-2-ones
    D Kaminskyy, I Subtel’na, A Pyrih, D Shtoyko, A Susel, A Gzella, R Lesyk
    Synlett 28 (07), 811-814 , 2017
    2017
    Citations: 12
  • 5‐Arylidene‐2‐(4‐hydroxyphenyl)aminothiazol‐4(5 H )‐ones with selective inhibitory activity against some leukemia cell lines
    I Subtelna, A Kryshchyshyn‐Dylevych, R Jia, M Lelyukh, A Ringler, ...
    Archiv der Pharmazie 354 (4), 2000342 , 2021
    2021
    Citations: 11
  • Сучасні підходи до моделювання лікарських засобів
    РБ Лесик, БП Громовик, ДВ Атаманюк, ІЮ Субтельна, ІІ Соронович
    Фармац. журн, 33-39 , 2002
    2002
    Citations: 5
  • SzymaÅ „ska E, Kieć-Kononowicz K, Zimenkovsky, B, Vasylenko O, Gzella A, Lesyk R. Synthesis of 5-arylidene-2-amino-4-azolones and evaluation of their anticancer activity
    I Subtel’na, D Atamanyuk
    Bioorg Med Chem 18, 5090-102 , 2010
    2010
    Citations: 4
  • Anticancer cytotoxicity of indole-thiazolidinone hybrids, in silico study of mechanisms of their action
    AP Kryshchyshyn-Dylevych, IY Subtelna, NS Finiuk, L Radko, ...
    Biopolymers and Cell 38 (4), 257-277 , 2022
    2022
    Citations: 2
  • In sIlIco identification and biochemical validation of plausible molecular targets of 4-thiazolidinone derivative les-3833 as a potential anticancer agent
    RL L. KоbylinsKa, D. Khylyuk, I. Subtelna, M. Kitsera
    Ukrainian Biochemical Journal 93 (2), 7-22 , 2021
    2021
    Citations: 1
  • Synthesis and antitumor activity evaluation of new 2-(4-alkоxyphenylamino) thiazol-4 (5H)-оnes derivatives
    I Subtel’na, B Zimenkovsky, R Lesyk
    Current Issues in Pharmacy and Medical Sciences 23 (3), 231-235 , 2010
    2010
    Citations: 1
  • Протипухлинна цитотоксичність індол-тіазолідинонових гібридів та in silico дослідження механізму їхньої дії
    АП Крищишин-Дилевич, ІЮ Субтельна, НС Фінюк, Л Радко, ...
    Biopolymers and Cell 38 (4), 257-277 , 2022
    2022
  • Синтез, превращения и биологическая активность функциональнозамещенных 2-амино-2-тиазолин-4-онов и 2(4)-имино-4(2)-тиазолидинонов
    Д.Я. Гаврилюк, И.Ю. Субтельная, Б.С. Зименковский
    “Химия и биологическая активность азолов” (Избранные обзоры) под редакцией В … , 2014
    2014
  • Rational design of potential anticancer" drug-like" molecules based on 4-azoldinone scaffold
    R Lesyk, B Zimenkovsky, D Kaminskyy, D Havryluk, D Atamanyuk, ...
    EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS 40, 109-109 , 2011
    2011
  • RECOOP Biopolymers and Cell
    SG Vari
    Biopolymers & Cell 27 (2) , 2011
    2011
  • Тіазолідинони як лейтмотив у створенні протиракових лікарських засобів. Досвід наукової групи з медичної хімії ЛНМУ імені Данила Галицького
    РБ Лесик, БС Зіменковський, ДВ Камінський, АП Крищишин, ...
    Biopolymers and Cell 27 (2), 107-117 , 2011
    2011
  • СИНТЕЗ И ИЗУЧЕНИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТИ ПРОИЗВОДНЫХ 2-(4-АЛКОКСИ-ФЕНИЛАМИНО) ТИАЗОЛ-4 (5Н)-ОНОВ
    ІЮ Субтельна, БС Зіменковський, РБ Лесик
    Журнал органічної та фармацевтичної хімії 8 (3), 58-64 , 2010
    2010